OTCMKTS:OTLC Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free OTLC Stock Alerts $0.04 +0.00 (+2.78%) (As of 05/24/2024 08:51 PM ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.01▼$0.05Volume265,500 shsAverage Volume67,753 shsMarket Capitalization$15.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Oncotelic Therapeutics alerts: Email Address Ad Chaikin AnalyticsWall Street Legend Warns: "A Strange Day Is Coming to America"Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more. About Oncotelic Therapeutics Stock (OTCMKTS:OTLC)Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.Read More OTLC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLC Stock News HeadlinesMay 20, 2024 | globenewswire.comONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETINGMay 19, 2024 | morningstar.comOncotelic Therapeutics Inc OTLCMay 16, 2024 | finance.yahoo.comONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024March 25, 2024 | finance.yahoo.comLinkage of Cancer and Lupus in Gliomas PatientsMarch 25, 2024 | globenewswire.comLinkage of Cancer and Lupus in Gliomas PatientsMarch 4, 2024 | globenewswire.comInvitation to Participate in STOP-PC Clinical TrialFebruary 22, 2024 | benzinga.comOncotelic Therapeutics Stock (OTC:OTLC) Earnings Dates and Earning CallsFebruary 3, 2024 | msn.comOncotelic Therapeutics Strikes Material Definitive Legal AgreementJanuary 23, 2024 | morningstar.comLineage Cell Therapeutics Inc LCTXDecember 18, 2023 | finance.yahoo.comOncotelic Therapeutics Announces Opening of GMP Manufacturing PlantNovember 15, 2023 | finanznachrichten.deOncotelic Therapeutics, Inc.: Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsNovember 15, 2023 | msn.comOncotelic Therapeutics reports Q3 resultsNovember 15, 2023 | finance.yahoo.comOncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsSeptember 11, 2023 | benzinga.comThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The ChargeSeptember 11, 2023 | benzinga.comThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The ChargeAugust 25, 2023 | finance.yahoo.comOncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023August 23, 2023 | finance.yahoo.comSapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic CancerMay 16, 2023 | finance.yahoo.comOncotelic Participating at 2023 BIO International ConventionApril 24, 2023 | technews.tmcnet.comOncotelic Launches PDAO SEC ChatbotApril 20, 2023 | seekingalpha.comOncotelic Therapeutics reports FY resultsApril 19, 2023 | finance.yahoo.comOncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model TechnologyMarch 13, 2023 | technews.tmcnet.comHigh Intra-Tumor TGF-ß2 Predicts Poor Survival in Pediatric Cancer of the BrainstemFebruary 15, 2023 | seekingalpha.comOTLC Oncotelic Therapeutics, Inc.February 6, 2023 | finance.yahoo.comOncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell CancerJanuary 25, 2023 | finance.yahoo.comOncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic CancerSee More Headlines Receive OTLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/19/2021Today5/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:OTLC CUSIPN/A CIK908259 Webwww.mateon.com Phone(650) 635-7000Fax650-635-7001Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,900,000.00 Net MarginsN/A Pretax Margin-11,535.72% Return on Equity-65.10% Return on Assets-25.41% Debt Debt-to-Equity Ratio0.20 Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual Sales$70,000.00 Price / Sales214.74 Cash Flow$0.01 per share Price / Cash Flow2.90 Book Value$0.03 per share Price / Book1.23Miscellaneous Outstanding Shares406,270,000Free Float246,931,000Market Cap$15.03 million OptionableNot Optionable Beta0.03 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Vuong Trieu Ph.D. (Age 61)Chairman & CEO Mr. Amit Shah (Age 57)Chief Financial Officer Dr. Anthony E. Maida III (Age 72)B.A., MA, MBA, Ph.D., Chief Medical Officer Translation Medicine & Director Mr. Saranjit Saund (Age 66)CBO & GM of AI Division Mr. Steven W. King (Age 60)Consultant & Director Dr. Larn Hwang (Age 61)Chief Scientific Officer Dr. Seymour Howard Fein M.D. (Age 75)Chief Regulatory Officer & Chief Medical Officer Mr. Burcak BeserCTO of AI DivisionMore ExecutivesKey CompetitorsMIRA PharmaceuticalsNASDAQ:MIRAKiora PharmaceuticalsNASDAQ:KPRXPurple BiotechNASDAQ:PPBTInhibitor TherapeuticsOTCMKTS:INTIPieris PharmaceuticalsNASDAQ:PIRSView All Competitors OTLC Stock Analysis - Frequently Asked Questions How have OTLC shares performed in 2024? Oncotelic Therapeutics' stock was trading at $0.0383 at the start of the year. Since then, OTLC stock has decreased by 3.4% and is now trading at $0.0370. View the best growth stocks for 2024 here. Are investors shorting Oncotelic Therapeutics? Oncotelic Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 400 shares, a drop of 77.8% from the April 30th total of 1,800 shares. Based on an average daily volume of 30,300 shares, the days-to-cover ratio is presently 0.0 days. View Oncotelic Therapeutics' Short Interest. How were Oncotelic Therapeutics' earnings last quarter? Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) posted its earnings results on Thursday, August, 19th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. How do I buy shares of Oncotelic Therapeutics? Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OTLC) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsWARNING about the death of the U.S. dollar…Colonial MetalsThe only AI company to buyPorter & CompanyBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsPresident Biden just made a shocking moveStansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
